Predicting Lung Health in Sarcoidosis with Vitamin D Metabolism
Official title: Development of Clinical Prediction Models for Pulmonary Outcomes in Sarcoidosis: Vitamin D Metabolism
Funded at University of California, San Francisco · NIH-11451047 · Data updated 2026-11-12
Aging individuals with sarcoidosis, especially Black/African American women, may benefit from a clearer plan that uses vitamin D biology to predict and improve lung health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 1, 2022 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $844,722 |
| NIH project number | 2R01HL157533-05 |
| Project ID | NIH-11451047 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with sarcoidosis, particularly Black/African American women with low vitamin D levels, who are undergoing standard therapy.
✕Less likely to help
Patients without sarcoidosis or those with normal vitamin D status may see limited relevance.
What this research studies
This project aims to connect vitamin D metabolism with lung function in people with sarcoidosis, focusing on those most affected by the disease. Researchers will analyze vitamin D-related markers and lung measurements to build practical prediction tools. The team will explore how vitamin D levels relate to symptoms, bone health, and tolerance to standard therapies, and will study how individuals vary in response to vitamin D. By understanding these connections, clinicians could tailor vitamin D-related strategies to improve respiratory outcomes and quality of life.
Why it matters
Potential benefit: If successful, patients could receive personalized vitamin D–based approaches to help manage lung symptoms and reduce treatment-related risks.
How similar studies have gone: Preliminary findings suggest vitamin D status is linked to lung function, but deeper mechanistic work is needed to guide therapy.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Koth, Laura L — University of California, San Francisco
- Study coordinator: Koth, Laura L
Related research
Other NIH-funded projects on the same topics.
-
Integrative metabolomics to improve sarcoidosis diagnosis and prognosis
A research project from UCLA aims to find blood-based biomarkers that help diagnose sarcoidosis earlier and predict how it will progress, especially in African American women.
-
Understanding how inflammation and scarring develop in pulmonary sarcoidosis
A doctor-scientist is studying why some people with sarcoidosis develop dangerous lung scarring and how to prevent it.
-
Peptide-based Diagnostic Test for Sarcoidosis
A new test using peptide-based ELISA is being developed to diagnose sarcoidosis, potentially reducing the need for invasive lung biopsies.
-
Molecular markers of progressive pulmonary sarcoidosis
This grant looks at proteins and genes in people with sarcoidosis to find early signs that the disease will worsen from the lungs.
-
Advanced imaging to monitor immune-suppressant therapy in active cardiac sarcoidosis
A patient-focused imaging study to see how MRI and PET 18F-FDG can track how well immune-suppressant treatment is working for active cardiac sarcoidosis.
-
Understanding why sarcoidosis happens and how it affects people using multi-omics
A multi-omics study aims to uncover why sarcoidosis affects people differently and to find biomarkers that predict disease burden.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.